Literature DB >> 2504577

Management of diabetic ketoacidosis.

T H Sanson1, S N Levine.   

Abstract

Diabetic ketoacidosis is an all too frequent and sometimes preventable complication of Type I diabetes mellitus, responsible for significant morbidity and mortality within the diabetic population. Precipitating diseases account for the majority of deaths occurring in patients admitted in diabetic ketoacidosis, but some deaths are still attributable to ketoacidosis alone, despite recent advances in therapy and management. Recognition of the ketoacidotic state is paramount to optimal therapy, and often hinges on the diagnostic acumen of the physician. Since 20 to 30% of patients presenting in diabetic ketoacidosis do so as the initial manifestation of their previously undiagnosed disease, physicians must maintain a high level of suspicion for this condition. Understanding the pathogenetic mechanisms leading to and prevailing in diabetic ketoacidosis will allow physicians to intervene in a rational manner, approaching therapy with specific end-points in mind: (a) restoration of optimal volume status; (b) reversal of acidosis; (c) reduction of serum glucose levels; (d) replacement of specific electrolytes in a timely manner; (c) institution of appropriate therapy for any precipitating cause; and, (f) careful monitoring of the patient's biochemical, physical and mental parameters to allow adjustment in therapy as necessary. The mainstay of treatment for diabetic ketoacidosis is appropriate fluid and insulin therapy. Low-dose intravenous infusion is now the accepted mode of insulin delivery for patients with this condition. Potassium replacement is almost always necessary, often requiring massive amounts of this ion due to the total body depletion seen with the development of ketoacidosis. Controversy still surrounds routine use of phosphate in diabetic ketoacidosis but replacement may be needed if serum levels fall toward the lower limits of normal values, to avoid the potential adverse effects of phosphate depletion. Administration of bicarbonate is also controversial and should be reserved for patients whose pH is less than 7.0 to 7.1 and then it should be added to intravenous fluids, not given as an intravenous bolus. Efforts toward preventing diabetic ketoacidosis should be of prime importance to physician and patient alike. Preventive measures should include patient education about diabetes mellitus, precipitating factors of diabetic ketoacidosis, signs and symptoms of early metabolic decompensation, rational insulin therapy during minor illness and appropriate timing of physician contact to help avoid this serious and sometimes fatal complication of diabetes mellitus.

Entities:  

Mesh:

Year:  1989        PMID: 2504577     DOI: 10.2165/00003495-198938020-00008

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  40 in total

1.  Ketogenesis and its regulation.

Authors:  J D McGarry; D W Foster
Journal:  Am J Med       Date:  1976-07       Impact factor: 4.965

2.  Cerebral oedema in diabetic ketoacidosis.

Authors:  R Matz
Journal:  Lancet       Date:  1987-09-19       Impact factor: 79.321

3.  Treatment of diabetic ketoacidosis.

Authors:  S N Levine; J E Loewenstein
Journal:  Arch Intern Med       Date:  1981-05

4.  The effect on mortality of low-dose insulin therapy for diabetic ketoacidosis.

Authors:  M C Sheppard; A D Wright
Journal:  Diabetes Care       Date:  1982 Mar-Apr       Impact factor: 19.112

Review 5.  Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use.

Authors:  R N Brogden; R C Heel
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

6.  Comparison of efficacy of human and porcine insulin in treatment of diabetic ketoacidosis.

Authors:  F E Storms; J A Lutterman; A van't Laar
Journal:  Diabetes Care       Date:  1987 Jan-Feb       Impact factor: 19.112

7.  Epidemiology and treatment of diabetic ketoacidosis in a community population.

Authors:  K Ellemann; J N Soerensen; L Pedersen; B Edsberg; O O Andersen
Journal:  Diabetes Care       Date:  1984 Nov-Dec       Impact factor: 19.112

8.  Efficiency of human insulin (recombinant DNA) in the treatment of diabetic ketoacidosis and severe nonketoacidotic hyperglycemia.

Authors:  W Bachmann; H Walter; N Lotz; H Mehnert
Journal:  Diabetes Care       Date:  1982 Nov-Dec       Impact factor: 19.112

9.  Diabetic ketoacidosis in a community-based population.

Authors:  D D Johnson; P J Palumbo; C P Chu
Journal:  Mayo Clin Proc       Date:  1980-02       Impact factor: 7.616

10.  Low-dose insulin infusion in the treatment of diabetic ketoacidosis: bolus versus no bolus.

Authors:  P Fort; S M Waters; F Lifshitz
Journal:  J Pediatr       Date:  1980-01       Impact factor: 4.406

View more
  3 in total

Review 1.  Emergency management of diabetic ketoacidosis in adults.

Authors:  R D Hardern; N D Quinn
Journal:  Emerg Med J       Date:  2003-05       Impact factor: 2.740

Review 2.  Rational treatment of acid-base disorders.

Authors:  M L McLaughlin; J P Kassirer
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

Review 3.  Treatment of hyperglycaemic hyperosmolar non-ketotic syndrome.

Authors:  S N Levine; T H Sanson
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.